178 related articles for article (PubMed ID: 24107908)
1. Prognostic factors for recurrence-free survival in patients with HER2-positive early-stage breast cancer treated with adjuvant trastuzumab.
Tonyali O; Coskun U; Sener N; Inanc M; Akman T; Ulas A; Yazilitas D; Bal O; Kucukoner M; Yildirim Ozdemir N; Demirci U; Gunaydin Y; Yildiz R; Karaca H; Umit Unal O; Gumus M; Benekli M; Buyukberber S
Onkologie; 2013; 36(10):554-8. PubMed ID: 24107908
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
3. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
[TBL] [Abstract][Full Text] [Related]
5. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
Peterson DJ; Truong PT; Sadek BT; Alexander CS; Wiksyk B; Shenouda M; Raad RA; Taghian AG
Ann Surg Oncol; 2014 Oct; 21(11):3490-6. PubMed ID: 24841346
[TBL] [Abstract][Full Text] [Related]
6. Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.
Ulas A; Kos T; Avci N; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
Asian Pac J Cancer Prev; 2015; 16(4):1643-9. PubMed ID: 25743846
[TBL] [Abstract][Full Text] [Related]
7. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?
Ulas A; Avci N; Kos T; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
J BUON; 2015; 20(3):714-22. PubMed ID: 26214622
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer.
Kiess AP; McArthur HL; Mahoney K; Patil S; Morris PG; Ho A; Hudis CA; McCormick B
Cancer; 2012 Apr; 118(8):1982-8. PubMed ID: 21887681
[TBL] [Abstract][Full Text] [Related]
9. The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of relapse.
Hartkopf AD; Banys M; Meier-Stiegen F; Hahn M; Röhm C; Hoffmann J; Helms G; Taran FA; Wallwiener M; Walter C; Neubauer H; Wallwiener D; Fehm T
Breast Cancer Res Treat; 2013 Apr; 138(2):509-17. PubMed ID: 23494674
[TBL] [Abstract][Full Text] [Related]
10. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
Chang HR; Glaspy J; Allison MA; Kass FC; Elashoff R; Chung DU; Gornbein J
Cancer; 2010 Sep; 116(18):4227-37. PubMed ID: 20549829
[TBL] [Abstract][Full Text] [Related]
11. Real-world outcomes of different treatments in the management of patients with HER-2 positive breast cancer: a retrospective study.
Chitapanarux I; Trakultivakorn H; Srisukho S; Somwangprasert A; Watcharachan K; Srikawin J; Chaiwun B; Traisathit P
J Med Assoc Thai; 2013 Jun; 96(6):709-15. PubMed ID: 23951829
[TBL] [Abstract][Full Text] [Related]
12. Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC).
Stemmler HJ; Kahlert S; Siekiera W; Untch M; Heinrich B; Heinemann V
Onkologie; 2005 Nov; 28(11):582-6. PubMed ID: 16249644
[TBL] [Abstract][Full Text] [Related]
13. Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.
Montemurro F; Redana S; Viale G; Sanna G; Donadio M; Valabrega G; del Curto B; Bottini A; Botti G; dei Tos AP; Jacomuzzi ME; Di Bonito M; Danese S; Clavarezza M; Kulka J; Di Palma S; Durando A; Sapino A; Aglietta M
Clin Breast Cancer; 2008 Oct; 8(5):436-42. PubMed ID: 18952558
[TBL] [Abstract][Full Text] [Related]
14. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
Pinto AC; Ades F; de Azambuja E; Piccart-Gebhart M
Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.
Nishimura R; Okumura Y; Arima N
Breast Cancer; 2008; 15(1):57-64. PubMed ID: 18224396
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab.
Chan A; McGregor SR
Intern Med J; 2012 Mar; 42(3):267-74. PubMed ID: 21241440
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.
Braccini AL; Azria D; Thezenas S; Romieu G; Ferrero JM; Jacot W
Breast; 2013 Oct; 22(5):993-8. PubMed ID: 23831232
[TBL] [Abstract][Full Text] [Related]
20. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.
Chia S; Norris B; Speers C; Cheang M; Gilks B; Gown AM; Huntsman D; Olivotto IA; Nielsen TO; Gelmon K
J Clin Oncol; 2008 Dec; 26(35):5697-704. PubMed ID: 19001334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]